Zinostatin stimalamer

Drug Profile

Zinostatin stimalamer

Alternative Names: Neocarzinostatin, conjugate with styrene maleic acid anhydride copolymer; Poly(maleic acid-styrene)neocarzinostatin; SMANCS; YM 881; Zinostatin stimalamer

Latest Information Update: 11 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kumamoto University
  • Developer Astellas Pharma; Kayaku; Kumamoto University; Kuraray
  • Class Cytostatic antibiotics; Enediynes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer
  • No development reported Brain cancer

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 26 Jul 2001 A clinical study in renal cell carcinoma has been added to the Cancer therapeutic trials section
  • 26 Sep 1997 A study in patients with liver cancer has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top